Bicycle Therapeutics plc
NASDAQ:BCYCBiotechnology
-$0.06 today
- Market cap
- $217.99M
- Beta
- 1.54
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$3.14
Volume 0.57M
Average 0.49M
Income Statement
Follow revenue through to earnings.
Revenue
$72.59M
FY 2025 · Annual
+105.8% YoYOperating Income
-$247.72M
FY 2025 · Annual
Net Income
-$218.96M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 11.7M | 14.46M | 26.98M | 35.28M | 72.59M |
| Cost of Revenue | 0 | 0 | 156.5M | 172.97M | 0 |
| Gross Profit | 11.7M | 14.46M | (129.52M) | (137.69M) | 72.59M |
| Gross Margin | 100.0% | 100.0% | -480.1% | -390.3% | 100.0% |
| Research & Development | 44.88M | 81.61M | 156.5M | 172.97M | 240.28M |
| Selling, General & Admin | 32.44M | 49.51M | 59.83M | 71.46M | 80.02M |
| Operating Expenses | 77.32M | 131.12M | 60.43M | 72.18M | 320.3M |
| Depreciation & Amortization | 1.41M | 3.69M | 6.55M | 7.18M | 6.42M |
| EBITDA | (64.09M) | (107.21M) | (169.4M) | (164.89M) | (212.18M) |
| EBITDA Margin | -547.9% | -741.3% | -628.0% | -467.4% | -292.3% |
| Operating Income | (65.62M) | (116.65M) | (189.95M) | (209.87M) | (247.72M) |
| Operating Margin | -561.0% | -806.6% | -704.1% | -595.0% | -341.3% |
| Interest Income | 120K | 5.76M | 14M | 34.28M | 28.46M |
| Interest Expense | 2.98M | 3.34M | 3.26M | 1.73M | 206K |
| Other Income / Expenses | (2.86M) | 2.41M | 10.74M | 36.08M | 28.91M |
| Income Before Tax | (68.48M) | (114.24M) | (179.21M) | (173.8M) | (218.81M) |
| Pre-Tax Margin | -585.5% | -789.9% | -664.3% | -492.7% | -301.4% |
| Income Tax Expense | (1.66M) | (1.52M) | 1.46M | (4.77M) | 152K |
| Net Income | (66.82M) | (112.72M) | (180.66M) | (169.03M) | (218.96M) |
| Net Margin | -571.2% | -779.3% | -669.7% | -479.2% | -301.7% |
| EPS (Basic) | (2.67) | (3.80) | (5.08) | (2.91) | (3.16) |
| EPS (Diluted) | (2.67) | (3.80) | (5.08) | (2.90) | (3.16) |
| 25.06M | 29.66M | 35.59M | 58.21M | 69.28M | |
| 25.06M | 29.66M | 35.59M | 58.21M | 69.28M |
BCYC Earnings Waterfall · TTM
NASDAQ:BCYC · Revenue to Net Income
Key Ratios
Analysis
$63.5M of revenue converted into -$219.0M of net income for the selected period. Gross margin is -508.1% and net margin is -2526.7%, showing how much revenue survives after costs and taxes. EPS is $-3.15, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | |
| 8-K | Current report | Oct 29, 2026 | |
| 4/A | 4/A filing | Oct 7, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 6, 2026 |
How much revenue does BCYC generate?
Bicycle Therapeutics plc (BCYC) reported $72.59M of revenue in fiscal 2025.
Is BCYC profitable?
Bicycle Therapeutics plc (BCYC) reported -$218.96M of net income, with a net margin of -301.7%.
Continue the stock analysis
Jump to another research area for this company.